主要文件

查看所有文档

U1752

尿苷5-单磷酸

Name: 尿苷5-单磷酸
Brand: SIGMA

≥98%, natural (organic), powder

别名:

U 5′-P, UMP, 尿苷酸

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₉H₁₃N₂O₉P

化学文摘社编号:

58-97-9

分子量:

324.18

NACRES:

NA.51

PubChem Substance ID:

24900628

UNSPSC Code:

41106305

EC Number:

200-408-0

MDL number:

MFCD00067346

Assay:

≥98%

Biological source:

natural (organic)

Form:

powder

Solubility:

H₂O: soluble 50 mg/mL, clear, colorless

Storage temp.:

−20°C

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

产品名称

尿苷5-单磷酸, ≥98%

biological source

natural (organic)

Quality Level

200

assay

≥98%

form

powder

solubility

H₂O: soluble 50 mg/mL, clear, colorless

storage temp.

−20°C

SMILES string

OC1C(O)C(OC1COP(O)(O)=O)N2C=CC(=O)NC2=O

InChI

1S/C9H13N2O9P/c12-5-1-2-11(9(15)10-5)8-7(14)6(13)4(20-8)3-19-21(16,17)18/h1-2,4,6-8,13-14H,3H2,(H,10,12,15)(H2,16,17,18)

InChI key

DJJCXFVJDGTHFX-UHFFFAOYSA-N

说明

General description

尿苷5′-单磷酸盐可用作所有嘧啶核苷酸的前体。

Application

5′-尿苷单磷酸可作为等渗溶液伤口屏障重建实验中E3等渗液的组分，研究其对等渗液中基底细胞反应或上皮细胞向伤口迁移的影响。

Biochem/physiol Actions

5′-尿苷单磷酸(UMP)是RNA中的一种核苷酸单体，由核碱基尿嘧啶、核糖和磷酸组成。UMP作为膳食补充剂可增强神经递质释放和神经突生长，也可促进成年大鼠膜磷脂的生产。对成年沙鼠联合喂饲DHA和UMP后，树突棘和神经元膜合成增加。表明UMP可用于突触缺失引起的认知障碍治疗。

wgk

WGK 3

存储类别

11 - Combustible Solids

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

实验方案

LC/MS Analysis of Nucleotides on SeQuant ZIC-cHILIC

HILIC separation is an alternative that permits sensitive MS detection and without the use of ion-pair reagents.

LC/MS Analysis of Nucleotides SeQuant^® ZIC^®-cHILIC – Effect of pH

ZIC^®-cHILIC is a densely bonded zwitterionic stationary phase with phosphorylcholine functional groups covalently attached to silica.

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.

Nezam Afdhal et al.

The New England journal of medicine, 370(16), 1483-1493 (2014-04-15)

Effective treatment for hepatitis C virus (HCV) genotype 1 infection in patients who have not had a sustained virologic response to prior interferon-based therapy represents an unmet medical need. We conducted a phase 3, randomized, open-label study involving patients infected

Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.

Edward J Gane et al.

The New England journal of medicine, 368(1), 34-44 (2013-01-04)

The standard treatment for hepatitis C virus (HCV) infection is interferon, which is administered subcutaneously and can have troublesome side effects. We evaluated sofosbuvir, an oral nucleotide inhibitor of HCV polymerase, in interferon-sparing and interferon-free regimens for the treatment of

Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial.

Eric Lawitz et al.

The Lancet. Infectious diseases, 13(5), 401-408 (2013-03-19)

Protease inhibitors have improved treatment of infection with hepatitis C virus (HCV), but dosing, a low barrier to resistance, drug interactions, and side-effects restrict their use. We assessed the safety and efficacy of sofosbuvir, a uridine nucleotide analogue, in treatment-naive

查看所有相关文献

全球贸易项目编号

货号	GTIN
U1752-1G	04061837409363